Bayer lifts 2026 outlook as third-quarter sales rise on pharma growth
Bayer reported third-quarter sales up 4.1% and raised its 2026 EBITDA and free cash flow guidance, driven by its pharmaceuticals division.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Germany-based life sciences group Bayer said third-quarter sales rose 4.1% year on year and adjusted EBITDA climbed 6.9%, Reuters reported. The pharmaceuticals division led the gains, helped by strong sales of Nubeqa and Kerendia, along with growth in radiology and Beyonttra.
Other divisions were mixed. Crop Science sales fell on regulatory effects and adverse weather across Europe, the Middle East, Africa and Asia-Pacific, while Consumer Health sales were flat.
why it matters
The key signal for markets is the higher guidance. Bayer now expects 2026 EBITDA before special items of EUR 9.8-10.3 billion and has improved its free cash flow forecast to between minus EUR 1.5 billion and minus EUR 0.5 billion. Core earnings per share fell, however, weighed by non-cash charges tied to interest rate changes, and the quarter ended with a net loss of EUR 672 million. Analysts on average rate the shares a buy.
market impact
Bayer shares: raised EBITDA guidance supports the stock, while the net loss and weak Crop Science limit gains
- Bayer shares pressure up — raised EBITDA and cash flow guidance supports sentiment
tags
instruments
sources
- Germany's Bayer Q3 sales rise on growth in pharmaceuticals division, lifts outlook — Reuters, 3 November 2026 at 06:41 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗